Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05869669Phase 2Completed

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Role: collaborator

NCT07033481Phase 2Recruiting

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

Role: collaborator

NCT06815965Phase 2Completed

A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Role: collaborator

NCT06987643Phase 2Recruiting

A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke

Role: collaborator

All 4 trials loaded